Anthem Biosciences: Substantial Acquisition Disclosure under SEBI Takeover Code

M&A / JV 23 Jun 2026 · Filed / open· ✓ Verified

The filing constitutes a formal disclosure by Ajay Bhardwaj under Regulations 31(4) and 31(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, indicating a crossing of one or more prescribed shareholding thresholds in Anthem Biosciences Limited. No public announcement of acquisition quantum, consideration or terms is currently available in secondary sources. Anthem Biosciences is a drug-discovery and biotech research company listed on NSE/BSE. The disclosure was submitted to NSE on 23 June 2026.

Why it mattersDisclosure triggers mandatory transparency of shareholding thresholds; acquirer and target board must monitor ongoing regulatory compliance milestones under takeover code (open offer thresholds, voting agreements, pledges).
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals